Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
BOSTON--(BUSINESS WIRE)--May 16, 2019--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 20 th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005067/en/
CONTACT: Verastem Oncology:
Vice President, Investor Relations & Finance
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Verastem Oncology
Copyright Business Wire 2019.
PUB: 05/16/2019 07:00 AM/DISC: 05/16/2019 07:00 AM